Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/80360
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Glucagon-like peptides 1 and 2 in health and disease: A review |
Author: | Marathe, C. Rayner, C. Jones, K. Horowitz, M. |
Citation: | Peptides, 2013; 44:75-86 |
Publisher: | Elsevier Science Inc |
Issue Date: | 2013 |
ISSN: | 0196-9781 1873-5169 |
Statement of Responsibility: | Chinmay S. Marathe, Christopher K. Rayner, Karen L. Jones, Michael Horowitz |
Abstract: | The gut derived peptides, glucagon-like peptides 1 and 2 (GLP-1 and GLP-2), are secreted following nutrient ingestion. GLP-1 and another gut peptide, glucose-dependent insulinotropic polypeptide (GIP) are collectively referred to as 'incretin' hormones, and play an important role in glucose homeostasis. Incretin secretion shares a complex interdependent relationship with both postprandial glycemia and the rate of gastric emptying. GLP-1 based therapies are now well established in the management of type 2 diabetes, while recent literature has suggested potential applications to treat obesity and protect against cardiovascular and neurological disease. The mechanism of action of GLP-2 is not well understood, but it shows promise as an intestinotropic agent. |
Keywords: | Pancreas Animals Humans Diabetes Mellitus, Type 2 Blood Glucose Receptors, Glucagon Gastric Emptying Postprandial Period Glucagon-Like Peptide 1 Glucagon-Like Peptide 2 Clinical Trials as Topic Incretins |
Rights: | © 2013 Elsevier Inc. All rights reserved. |
DOI: | 10.1016/j.peptides.2013.01.014 |
Published version: | http://www.sciencedirect.com/science/article/pii/S0196978113000338 |
Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.